Tiedemann Advisors LLC Sells 35,113 Shares of Johnson & Johnson (NYSE:JNJ)
Tiedemann Advisors LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 40.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,629 shares of the company’s stock after selling 35,113 shares during the period. Tiedemann Advisors LLC’s holdings in Johnson & Johnson were worth $7,335,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of JNJ. Virtus ETF Advisers LLC acquired a new position in Johnson & Johnson during the second quarter valued at approximately $25,000. Krane Funds Advisors LLC acquired a new position in Johnson & Johnson during the second quarter valued at approximately $26,000. Crewe Advisors LLC raised its position in Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Permanens Capital L.P. raised its position in Johnson & Johnson by 50.0% during the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares in the last quarter. Finally, Evolution Wealth Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $40,000. Institutional investors own 72.01% of the company’s stock.
JNJ has been the subject of several research analyst reports. Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Credit Suisse Group set a $156.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price target for the company. in a report on Thursday, July 18th. Finally, Raymond James lowered their price target on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating for the company in a report on Wednesday, July 17th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $150.60.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. Johnson & Johnson’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.10 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $0.95 dividend. The ex-dividend date was Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.93%. Johnson & Johnson’s payout ratio is 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: How does new data get added to a blockchain?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.